BioDuro announced a strategic partnership with CTI Biotechnology to leverage the complementary strengths of both companies across critical stages of preclinical R&D to establish an integrated platform spanning from drug discovery to investigational new drug (IND) submission, providing global biotech and pharmaceutical clients with more efficient and flexible development solutions.
Under the partnership, BioDuro will provide integrated capabilities including discovery chemistry, biology, drug metabolism and pharmacokinetics (DMPK), and pharmacology, as well as API and drug product development and manufacturing, together with IND filing support across global markets. CTI Biotechnology will contribute GLP toxicology studies and bioanalytical services in readiness for successful IND submission.